NIH Funding Announcements

Syndicate content
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 33 min 48 sec ago

Behavioral Interventions for Prevention of Opioid Use Disorder or Adjunct to Medication Assisted Treatment-SAMHSA Opioid STR Grants (R21/R33)

Thu, 11/16/2017 - 10:21
Funding Opportunity RFA-AT-18-002 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to solicit applications to examine the impact of behavioral interventions within the context of states plans for use of the SAMHSA Opioid STR grant funds authorized under the 21st Century Cures Act. Applications are encouraged for studies that examine the impact of interventions such as mindfulness meditation, cognitive behavioral therapy, or multi-disciplinary rehabilitation for primary or secondary prevention for opioid use disorder (OUD) or as an adjunct to medication assisted treatment (MAT) of OUD. Applications that emphasize treatment of the comorbidity of OUD and chronic pain are of particular interest.
Categories: NIH-Funding

Getting to Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Not Allowed)

Thu, 11/16/2017 - 10:13
Funding Opportunity PAR-18-411 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support grants to improve measurement and understanding of viral suppression and HIV transmission in the United States (U.S.) using population-level epidemiology and novel tools from Big Data science approaches and m/eHealth. The outcome of this research will uncover new knowledge from data to build more effective and context-specific HIV control strategies for the U.S. epidemic.
Categories: NIH-Funding

Notice of Upcoming Webinar for the Strong Heart Study (SHS) - Coordinating Center (CC) Solicitation

Thu, 11/16/2017 - 04:28
Notice NOT-HL-17-562 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

NINDS Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)

Wed, 11/15/2017 - 11:40
Funding Opportunity PA-18-358 from the NIH Guide for Grants and Contracts. The NINDS Exploratory Neuroscience Research Grant program supports exploratory and innovative research projects, which fall within the mission of the NINDS. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community.
Categories: NIH-Funding

Pilot and Feasibility Clinical Research Grants in Urologic Disorders (R21 Clinical Trial Optional)

Wed, 11/15/2017 - 11:29
Funding Opportunity PAR-18-101 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is to support Exploratory/Developmental Research Grants (R21) that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to urologic disorders research. Studies should address important clinical and translational questions that are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of prevention, diagnosis or treatment of urologic disorders.
Categories: NIH-Funding

Pilot and Feasibility Clinical Research Grants in Kidney Diseases (R21 Clinical Trial Optional)

Wed, 11/15/2017 - 11:16
Funding Opportunity PAR-18-100 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is to support Exploratory/Developmental Research Grants (R21) that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to kidney disease research. Studies should address important clinical and translational questions and are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of diagnosis, prevention, or treatment of kidney diseases.
Categories: NIH-Funding

Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)

Wed, 11/15/2017 - 11:14
Funding Opportunity PAR-18-018 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve any aspect of the cancer continuum and any phase of the translational spectrum.
Categories: NIH-Funding

Exploratory/Developmental Clinical Research Grants in Obesity (R21 Clinical Trial Optional)

Wed, 11/15/2017 - 11:12
Funding Opportunity PA-18-104 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research grant applications from institutions/organizations that propose to conduct exploratory/developmental clinical studies that will accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults and/or children. Exploratory epidemiological research with a goal of informing translational/clinical research will also be supported within this program.
Categories: NIH-Funding

Pilot and Feasibility Clinical and Translational Research Studies in Digestive Diseases and Nutrition (R21 Clinical Trial Optional)

Wed, 11/15/2017 - 11:10
Funding Opportunity PA-18-099 from the NIH Guide for Grants and Contracts. This FOA encourages pilot and feasibility clinical and translational research studies of digestive and liver diseases.
Categories: NIH-Funding

Oocyte Mitochondrial Function in Relation to Fertility, Aging, and Mitochondrial Diseases (R21 Clinical Trial Optional)

Wed, 11/15/2017 - 10:54
Funding Opportunity PA-18-093 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of oocyte mitochondrial function in relation to fertility, aging, and mitochondrial disease transmission to offspring. The overarching goal is to gain fundamental insight into the role of mitochondria and long-term consequences of their dysfunction in the oocyte, and to develop therapeutic or alternative approaches to treat mitochondrial dysfunction for improving oocyte quality and competency, and health of the resultant offspring. It is anticipated that the results from studies supported by this FOA will provide women, suffering from infertility or subfertility and other illnesses due to mitochondrial dysfunction, practical approaches to enhance their fertility and the well-being of their offspring. This funding opportunity announcement encourages innovative and high-risk/impact studies that may lead to breakthrough in mitochondrial function, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact in understanding and treatment of mitochondrial dysfunction.
Categories: NIH-Funding

AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)

Wed, 11/15/2017 - 10:53
Funding Opportunity PA-18-072 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks to facilitate the entry of both newly independent and early career investigators to the area of drug abuse research on HIV/AIDS. This FOA, AIDS-Science Track Award for Research Transition (A-START), encourages Small Research Grant (R03) applications to support research projects on drug abuse and HIV/AIDS that can be carried out in a short period of time with limited resources. Applications under this FOA are welcomed from all areas of HIV/AIDS research that NIDA supports.
Categories: NIH-Funding

Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34 Clinical Trial Optional)

Wed, 11/15/2017 - 10:48
Funding Opportunity PA-18-071 from the NIH Guide for Grants and Contracts. This FOA provides resources to support (a) pilot or feasibility studies of new or adapted interventions to prevent HIV infection among populations where substance use may be a contributing factor; (b) pilot or feasibility studies of new or adapted interventions to improve the care of HIV infection among populations where substance use is prevalent, including interventions that integrate treatment for substance use disorders and HIV infection; or (c) pilot or feasibility studies to increase the scale, uptake, delivery, and/or quality of HIV prevention or care interventions with established evidence of efficacy. Both primary and secondary prevention will be supported. The full range of substance use will be considered including problematic episodic use and substance use disorders, as well as a full range of substances and modes of administration. The most important consideration is that substance use may affect transmission directly as in the case of injection or may affect transmission risk behavior. Domestic and overseas populations will be considered, with particular attention to populations with disproportionate burden of HIV infection and those where HIV infection and/or drug use are emergent.
Categories: NIH-Funding

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R21 Clinical Trial Optional)

Wed, 11/15/2017 - 10:46
Funding Opportunity PA-18-070 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages R21 grant applications to conduct rigorous health services and economic research to maximize the delivery of efficient, high-quality drug, tobacco, and alcohol prevention, treatment, and recovery support services. Examples of such research include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation research; (4) economic and cost studies; and (5) development or improvement of research methodology, analytic approaches, and measurement instrumentation used in the study of drug, alcohol, and tobacco prevention, treatment, and recovery services.
Categories: NIH-Funding

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R03 Clinical Trial Optional)

Wed, 11/15/2017 - 10:44
Funding Opportunity PA-18-069 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages small grant applications (R03) to conduct rigorous health services and economic research to maximize the delivery of efficient, high-quality drug, tobacco, and alcohol prevention, treatment, and recovery support services. Examples of such research include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation research; (4) economic and cost studies; and (5) development or improvement of research methodology, analytic approaches, and measurement instrumentation used in the study of drug, alcohol, and tobacco prevention, treatment, and recovery services.
Categories: NIH-Funding

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Abuse (R34 Clinical Trial Optional)

Wed, 11/15/2017 - 10:33
Funding Opportunity PA-18-068 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies, designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability, and utility of these approaches.
Categories: NIH-Funding

Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34 Clinical Trial Optional)

Wed, 11/15/2017 - 10:29
Funding Opportunity PA-18-067 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) for R34 applications seeks to support: (a) pilot and/or feasibility testing of innovative new, revised, or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving andthe drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings; and (b) pre-trial feasibility testing for prevention services and systems research. It is expected that research conducted via this R34 mechanism will consist of early stage efficacy, effectiveness or services research that will provide intervention pilot and/or feasibility data that is a pre-requisite for preparing and submitting subsequent applications for larger scale drug or alcohol abuse prevention and/or drug- or alcohol-related HIV prevention intervention studies. This R34 FOA does not support applications for which the sole focus is development of intervention protocols, manuals, or the standardization of protocols; rather, any development work must be imbedded within a pilot/feasibility study.Of particular interest are prevention interventions targeting the healthcare system.
Categories: NIH-Funding

International Research Collaboration on Drug Abuse and Addiction Research (R21 Clinical Trial Optional)

Wed, 11/15/2017 - 10:27
Funding Opportunity PA-18-066 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the United States. Special opportunities include access to unusual talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery. Projects should have relevance to the mission of NIDA and where feasible should address NIDAs international scientific priority areas (http://www.drugabuse.gov/international/research-priorities). While the priorities will change from year to year, in FY15 priority areas include: linkages between HIV/AIDS and drug abuse; prevention, initiation, and treatment of nicotine and tobacco use (especially among vulnerable populations such as children, adolescents, pregnant women, and those with co-morbid disorders); the neuroscience of marijuana and cannabinoids; and the effect of changes in laws and policies on marijuana and its impact. The R21 activity code is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. Projects of limited cost or scope that use widely accepted approaches and methods within well-established fields are better suited for the R03 small grant activity code.
Categories: NIH-Funding

International Research Collaboration on Drug Abuse and Addiction Research (R03 Clinical Trial Optional)

Wed, 11/15/2017 - 10:24
Funding Opportunity PA-18-065 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the United States. Special opportunities include access to unusual talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery. Projects should have relevance to the mission of NIDA and where feasible should address NIDAs international scientific priority areas(http://www.drugabuse.gov/international/research-priorities). While the priorities will change from year to year, in FY15 priority areas include: linkages between HIV/AIDS and drug abuse; prevention, initiation, and treatment of nicotine and tobacco use (especially among vulnerable populations such as children, adolescents, pregnant women, and those with co-morbid disorders); the neuroscience of marijuana and cannabinoids; and the effect of changes in laws and policies on marijuana and its impact. The NIH R03 activity code supports discrete, well-defined projects that realistically can be completed in two years and that require limited levels of funding. The R03 activity code supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.
Categories: NIH-Funding

Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21 Clinical Trial Optional)

Wed, 11/15/2017 - 10:22
Funding Opportunity PA-18-052 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypotheses through the use of existing data sets.
Categories: NIH-Funding